US Patent

US11312718 — Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one

Formulation · Assigned to Infinity Pharmaceuticals Inc · Expires 2032-01-10 · 6y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent describes formulations of a chemical compound and methods for preparing it, which modulates kinase activity, including PI3 kinase activity.

USPTO Abstract

Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11312718
Jurisdiction
US
Classification
Formulation
Expires
2032-01-10
Drug substance claim
No
Drug product claim
Yes
Assignee
Infinity Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.